Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. Isolated DCs loaded with tumor antigen ex vivo and administered as a cellular vaccine are found to induce protective and therapeutic anti-tumor immunity in experimental animals.

The market is mainly driven by the significant applications of Dendritic Cell Cancer Vaccines in various end use industries. The expanding demands from the Pediatrics and Adults, are propelling Dendritic Cell Cancer Vaccines market. CreaVax, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Sipuleucel-T (Provenge) segment is estimated at % CAGR for the next seven-year period.

Among all the currently available immunotherapy strategies, dendritic cell vaccines are the most potent antigen-presenting cells for the effective proliferation of T-cells. The specificity of the treatment has boosted its range of applications and is also witnessing global acceptance. As a result, several companies are collaborating to introduce a novel product. For instance, in March 2022, BioNTech signed into a collaboration with Medigene by which Medigene received USD 29 million as an upfront research fund for the co-development of immunotherapies focusing on multiple types of carcinoma. Further, BioNTech will utilize Medigene’s discovery platform and successfully acquire a preclinical asset. Immunotherapy has great potential for treating minimal residual disease (MRD) by the use of dendritic cells and many studies have yielded promising results with no signs of recurrence of tumor growth. For instance, in May 2022, researchers of the AML-VACCiN consortium, clinically developed a dendritic cell vaccine- DCP-001, so as to vaccinate patients with acute myeloid leukemia to eradicate MRD and to effectively reduce the risk of a relapse. The vaccine candidate is designated as an orphan medicinal product in the EU after reliable results from trial phases I & II.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Dendritic Cell Cancer Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Dendritic Cell Cancer Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Dendritic Cell Cancer Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Dendritic Cell Cancer Vaccines sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Dendritic Cell Cancer Vaccines covered in this report include 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime and Sanpower Corporation, etc.

The global Dendritic Cell Cancer Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

3M Company

Activarti

Argos Therapeutics

Batavia Bioservices

Bellicum Pharmaceuticals

Creagene

DanDrit Biotech

DCPrime

Sanpower Corporation

Elios Therapeutics

ImmunoCellular Therapeutics

Immunicum

Kiromic

Medigene

Merck

Northwest Biotherapeutics

Glaxo Smith Kline

Tellaorporation

Vaxil BioTherapeutics

Scope of Dendritic Cell Cancer Vaccines - Market Report

Report Metric	Details
Report Name	Dendritic Cell Cancer Vaccines - Market
Forecasted market size in 2029	US$ 1436.3 million
CAGR	13.1%
Forecasted years	2023 - 2029
Global Dendritic Cell Cancer Vaccines market, by region:	North America (U.S., Canada, Mexico) Europe (Germany, France, UK, Italy, etc.) Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.) South America (Brazil, etc.) Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Dendritic Cell Cancer Vaccines market, Segment by Type:	CreaVax Sipuleucel-T (Provenge) Others
Global Dendritic Cell Cancer Vaccines market, by Application	Pediatrics Adults
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Dendritic Cell Cancer Vaccines companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

FAQ for this report

What is the Dendritic Cell Cancer Vaccines - Market size in 2029?

Ans: The Dendritic Cell Cancer Vaccines - Market size in 2029 will be US$ 1436.3 million.

What are the Application segmentation covered in the Dendritic Cell Cancer Vaccines - Market report?

Ans: The Applications covered in the Dendritic Cell Cancer Vaccines - Market report are Pediatrics, Adults

What are the Type segmentation covered in the Dendritic Cell Cancer Vaccines - Market report?

Ans: The Types covered in the Dendritic Cell Cancer Vaccines - Market report are CreaVax, Sipuleucel-T (Provenge), Others

1 Market Overview of Dendritic Cell Cancer Vaccines

1.1 Dendritic Cell Cancer Vaccines Market Overview

1.1.1 Dendritic Cell Cancer Vaccines Product Scope

1.1.2 Dendritic Cell Cancer Vaccines Market Status and Outlook

1.2 Global Dendritic Cell Cancer Vaccines Market Size Overview by Region 2018 VS 2022 VS 2029

1.3 Global Dendritic Cell Cancer Vaccines Market Size by Region (2018-2029)

1.4 Global Dendritic Cell Cancer Vaccines Historic Market Size by Region (2018-2023)

1.5 Global Dendritic Cell Cancer Vaccines Market Size Forecast by Region (2024-2029)

1.6 Key Regions, Dendritic Cell Cancer Vaccines Market Size (2018-2029)

1.6.1 North America Dendritic Cell Cancer Vaccines Market Size (2018-2029)

1.6.2 Europe Dendritic Cell Cancer Vaccines Market Size (2018-2029)

1.6.3 Asia-Pacific Dendritic Cell Cancer Vaccines Market Size (2018-2029)

1.6.4 Latin America Dendritic Cell Cancer Vaccines Market Size (2018-2029)

1.6.5 Middle East & Africa Dendritic Cell Cancer Vaccines Market Size (2018-2029)

2 Dendritic Cell Cancer Vaccines Market by Type

2.1 Introduction

2.1.1 CreaVax

2.1.2 Sipuleucel-T (Provenge)

2.1.3 Others

2.2 Global Dendritic Cell Cancer Vaccines Market Size by Type: 2018 VS 2022 VS 2029

2.2.1 Global Dendritic Cell Cancer Vaccines Historic Market Size by Type (2018-2023)

2.2.2 Global Dendritic Cell Cancer Vaccines Forecasted Market Size by Type (2024-2029)

2.3 Key Regions Market Size by Type

2.3.1 North America Dendritic Cell Cancer Vaccines Revenue Breakdown by Type (2018-2029)

2.3.2 Europe Dendritic Cell Cancer Vaccines Revenue Breakdown by Type (2018-2029)

2.3.3 Asia-Pacific Dendritic Cell Cancer Vaccines Revenue Breakdown by Type (2018-2029)

2.3.4 Latin America Dendritic Cell Cancer Vaccines Revenue Breakdown by Type (2018-2029)

2.3.5 Middle East and Africa Dendritic Cell Cancer Vaccines Revenue Breakdown by Type (2018-2029)

3 Dendritic Cell Cancer Vaccines Market Overview by Application

3.1 Introduction

3.1.1 Pediatrics

3.1.2 Adults

3.2 Global Dendritic Cell Cancer Vaccines Market Size by Application: 2018 VS 2022 VS 2029

3.2.1 Global Dendritic Cell Cancer Vaccines Historic Market Size by Application (2018-2023)

3.2.2 Global Dendritic Cell Cancer Vaccines Forecasted Market Size by Application (2024-2029)

3.3 Key Regions Market Size by Application

3.3.1 North America Dendritic Cell Cancer Vaccines Revenue Breakdown by Application (2018-2029)

3.3.2 Europe Dendritic Cell Cancer Vaccines Revenue Breakdown by Application (2018-2029)

3.3.3 Asia-Pacific Dendritic Cell Cancer Vaccines Revenue Breakdown by Application (2018-2029)

3.3.4 Latin America Dendritic Cell Cancer Vaccines Revenue Breakdown by Application (2018-2029)

3.3.5 Middle East and Africa Dendritic Cell Cancer Vaccines Revenue Breakdown by Application (2018-2029)

4 Dendritic Cell Cancer Vaccines Competition Analysis by Players

4.1 Global Dendritic Cell Cancer Vaccines Market Size by Players (2018-2023)

4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccines as of 2022)

4.3 Date of Key Players Enter into Dendritic Cell Cancer Vaccines Market

4.4 Global Top Players Dendritic Cell Cancer Vaccines Headquarters and Area Served

4.5 Key Players Dendritic Cell Cancer Vaccines Product Solution and Service

4.6 Competitive Status

4.6.1 Dendritic Cell Cancer Vaccines Market Concentration Rate

4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles

5.1 3M Company

5.1.1 3M Company Profile

5.1.2 3M Company Main Business

5.1.3 3M Company Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.1.4 3M Company Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.1.5 3M Company Recent Developments

5.2 Activarti

5.2.1 Activarti Profile

5.2.2 Activarti Main Business

5.2.3 Activarti Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.2.4 Activarti Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.2.5 Activarti Recent Developments

5.3 Argos Therapeutics

5.3.1 Argos Therapeutics Profile

5.3.2 Argos Therapeutics Main Business

5.3.3 Argos Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.3.4 Argos Therapeutics Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.3.5 Batavia Bioservices Recent Developments

5.4 Batavia Bioservices

5.4.1 Batavia Bioservices Profile

5.4.2 Batavia Bioservices Main Business

5.4.3 Batavia Bioservices Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.4.4 Batavia Bioservices Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.4.5 Batavia Bioservices Recent Developments

5.5 Bellicum Pharmaceuticals

5.5.1 Bellicum Pharmaceuticals Profile

5.5.2 Bellicum Pharmaceuticals Main Business

5.5.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.5.4 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.5.5 Bellicum Pharmaceuticals Recent Developments

5.6 Creagene

5.6.1 Creagene Profile

5.6.2 Creagene Main Business

5.6.3 Creagene Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.6.4 Creagene Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.6.5 Creagene Recent Developments

5.7 DanDrit Biotech

5.7.1 DanDrit Biotech Profile

5.7.2 DanDrit Biotech Main Business

5.7.3 DanDrit Biotech Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.7.4 DanDrit Biotech Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.7.5 DanDrit Biotech Recent Developments

5.8 DCPrime

5.8.1 DCPrime Profile

5.8.2 DCPrime Main Business

5.8.3 DCPrime Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.8.4 DCPrime Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.8.5 DCPrime Recent Developments

5.9 Sanpower Corporation

5.9.1 Sanpower Corporation Profile

5.9.2 Sanpower Corporation Main Business

5.9.3 Sanpower Corporation Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.9.4 Sanpower Corporation Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.9.5 Sanpower Corporation Recent Developments

5.10 Elios Therapeutics

5.10.1 Elios Therapeutics Profile

5.10.2 Elios Therapeutics Main Business

5.10.3 Elios Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.10.4 Elios Therapeutics Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.10.5 Elios Therapeutics Recent Developments

5.11 ImmunoCellular Therapeutics

5.11.1 ImmunoCellular Therapeutics Profile

5.11.2 ImmunoCellular Therapeutics Main Business

5.11.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.11.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.11.5 ImmunoCellular Therapeutics Recent Developments

5.12 Immunicum

5.12.1 Immunicum Profile

5.12.2 Immunicum Main Business

5.12.3 Immunicum Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.12.4 Immunicum Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.12.5 Immunicum Recent Developments

5.13 Kiromic

5.13.1 Kiromic Profile

5.13.2 Kiromic Main Business

5.13.3 Kiromic Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.13.4 Kiromic Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.13.5 Kiromic Recent Developments

5.14 Medigene

5.14.1 Medigene Profile

5.14.2 Medigene Main Business

5.14.3 Medigene Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.14.4 Medigene Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.14.5 Medigene Recent Developments

5.15 Merck

5.15.1 Merck Profile

5.15.2 Merck Main Business

5.15.3 Merck Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.15.4 Merck Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.15.5 Merck Recent Developments

5.16 Northwest Biotherapeutics

5.16.1 Northwest Biotherapeutics Profile

5.16.2 Northwest Biotherapeutics Main Business

5.16.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.16.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.16.5 Northwest Biotherapeutics Recent Developments

5.17 Glaxo Smith Kline

5.17.1 Glaxo Smith Kline Profile

5.17.2 Glaxo Smith Kline Main Business

5.17.3 Glaxo Smith Kline Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.17.4 Glaxo Smith Kline Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.17.5 Glaxo Smith Kline Recent Developments

5.18 Tellaorporation

5.18.1 Tellaorporation Profile

5.18.2 Tellaorporation Main Business

5.18.3 Tellaorporation Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.18.4 Tellaorporation Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.18.5 Tellaorporation Recent Developments

5.19 Vaxil BioTherapeutics

5.19.1 Vaxil BioTherapeutics Profile

5.19.2 Vaxil BioTherapeutics Main Business

5.19.3 Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions

5.19.4 Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2018-2023)

5.19.5 Vaxil BioTherapeutics Recent Developments

6 North America

6.1 North America Dendritic Cell Cancer Vaccines Market Size by Country (2018-2029)

6.2 U.S.

6.3 Canada

7 Europe

7.1 Europe Dendritic Cell Cancer Vaccines Market Size by Country (2018-2029)

7.2 Germany

7.3 France

7.4 U.K.

7.5 Italy

7.6 Russia

7.7 Nordic Countries

7.8 Rest of Europe

8 Asia-Pacific

8.1 Asia-Pacific Dendritic Cell Cancer Vaccines Market Size by Region (2018-2029)

8.2 China

8.3 Japan

8.4 South Korea

8.5 Southeast Asia

8.6 India

8.7 Australia

8.8 Rest of Asia-Pacific

9 Latin America

9.1 Latin America Dendritic Cell Cancer Vaccines Market Size by Country (2018-2029)

9.2 Mexico

9.3 Brazil

9.4 Rest of Latin America

10 Middle East & Africa

10.1 Middle East & Africa Dendritic Cell Cancer Vaccines Market Size by Country (2018-2029)

10.2 Turkey

10.3 Saudi Arabia

10.4 UAE

10.5 Rest of Middle East & Africa

11 Dendritic Cell Cancer Vaccines Market Dynamics

11.1 Dendritic Cell Cancer Vaccines Industry Trends

11.2 Dendritic Cell Cancer Vaccines Market Drivers

11.3 Dendritic Cell Cancer Vaccines Market Challenges

11.4 Dendritic Cell Cancer Vaccines Market Restraints

12 Research Finding /Conclusion

13 Methodology and Data Source

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

13.4 Author List

FEATURED COMPANIES

Bellicum Pharmaceuticals

ImmunoCellular Therapeutics

Northwest Biotherapeutics

Glaxo Smith Kline

Tellaorporation

Vaxil BioTherapeutics

List of Tables

Table 1. Global Market Dendritic Cell Cancer Vaccines Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029

Table 2. Global Dendritic Cell Cancer Vaccines Market Size by Region (2018-2023) & (US$ Million)

Table 3. Global Dendritic Cell Cancer Vaccines Market Size Share by Region (2018-2023)

Table 4. Global Dendritic Cell Cancer Vaccines Forecasted Market Size by Region (2024-2029) & (US$ Million)

Table 5. Global Dendritic Cell Cancer Vaccines Forecasted Market Size Share by Region (2024-2029)

Table 6. Global Dendritic Cell Cancer Vaccines Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029

Table 7. Global Dendritic Cell Cancer Vaccines Market Size by Type (2018-2023) & (US$ Million)

Table 8. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Type (2018-2023)

Table 9. Global Dendritic Cell Cancer Vaccines Forecasted Market Size by Type (2024-2029) & (US$ Million)

Table 10. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Type (2024-2029)

Table 11. North America Dendritic Cell Cancer Vaccines Revenue by Type (2018-2023) & (US$ Million)

Table 12. North America Dendritic Cell Cancer Vaccines Revenue by Type (2024-2029) & (US$ Million)

Table 13. Europe Dendritic Cell Cancer Vaccines Revenue by Type (2018-2023) & (US$ Million)

Table 14. Europe Dendritic Cell Cancer Vaccines Revenue by Type (2024-2029) & (US$ Million)

Table 15. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Type (2018-2023) & (US$ Million)

Table 16. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Type (2024-2029) & (US$ Million)

Table 17. Latin America Dendritic Cell Cancer Vaccines Revenue by Type (2018-2023) & (US$ Million)

Table 18. Latin America Dendritic Cell Cancer Vaccines Revenue by Type (2024-2029) & (US$ Million)

Table 19. Middle East and Africa Dendritic Cell Cancer Vaccines Revenue by Type (2018-2023) & (US$ Million)

Table 20. Middle East and Africa Dendritic Cell Cancer Vaccines Revenue by Type (2024-2029) & (US$ Million)

Table 21. Global Dendritic Cell Cancer Vaccines Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029

Table 22. Global Dendritic Cell Cancer Vaccines Market Size by Application (2018-2023) & (US$ Million)

Table 23. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Application (2018-2023)

Table 24. Global Dendritic Cell Cancer Vaccines Forecasted Market Size by Application (2024-2029) & (US$ Million)

Table 25. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Application (2024-2029)

Table 26. North America Dendritic Cell Cancer Vaccines Revenue by Application (2018-2023) & (US$ Million)

Table 27. North America Dendritic Cell Cancer Vaccines Revenue by Application (2024-2029) & (US$ Million)

Table 28. Europe Dendritic Cell Cancer Vaccines Revenue by Application (2018-2023) & (US$ Million)

Table 29. Europe Dendritic Cell Cancer Vaccines Revenue by Application (2024-2029) & (US$ Million)

Table 30. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Application (2018-2023) & (US$ Million)

Table 31. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Application (2024-2029) & (US$ Million)

Table 32. Latin America Dendritic Cell Cancer Vaccines Revenue by Application (2018-2023) & (US$ Million)

Table 33. Latin America Dendritic Cell Cancer Vaccines Revenue by Application (2024-2029) & (US$ Million)

Table 34. Middle East and Africa Dendritic Cell Cancer Vaccines Revenue by Application (2018-2023) & (US$ Million)

Table 35. Middle East and Africa Dendritic Cell Cancer Vaccines Revenue by Application (2024-2029) & (US$ Million)

Table 36. Global Dendritic Cell Cancer Vaccines Revenue (US$ Million) by Players (2018-2023)

Table 37. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Players (2018-2023)

Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccines as of 2022)

Table 39. Date of Key Players Enter into Dendritic Cell Cancer Vaccines Market

Table 40. Global Dendritic Cell Cancer Vaccines Key Players Headquarters and Area Served

Table 41. Dendritic Cell Cancer Vaccines Product Solution and Service

Table 42. Global Dendritic Cell Cancer Vaccines Players Market Concentration Ratio (CR5 and HHI)

Table 43. Mergers & Acquisitions, Expansion Plans

Table 44. 3M Company Basic Information List

Table 45. 3M Company Description and Business Overview

Table 46. 3M Company Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 47. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of 3M Company (2018-2023)

Table 48. 3M Company Recent Developments

Table 49. Activarti Basic Information List

Table 50. Activarti Description and Business Overview

Table 51. Activarti Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 52. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Activarti (2018-2023)

Table 53. Activarti Recent Developments

Table 54. Argos Therapeutics Basic Information List

Table 55. Argos Therapeutics Description and Business Overview

Table 56. Argos Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 57. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Argos Therapeutics (2018-2023)

Table 58. Argos Therapeutics Recent Developments

Table 59. Batavia Bioservices Basic Information List

Table 60. Batavia Bioservices Description and Business Overview

Table 61. Batavia Bioservices Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 62. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Batavia Bioservices (2018-2023)

Table 63. Batavia Bioservices Recent Developments

Table 64. Bellicum Pharmaceuticals Basic Information List

Table 65. Bellicum Pharmaceuticals Description and Business Overview

Table 66. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 67. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Bellicum Pharmaceuticals (2018-2023)

Table 68. Bellicum Pharmaceuticals Recent Developments

Table 69. Creagene Basic Information List

Table 70. Creagene Description and Business Overview

Table 71. Creagene Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 72. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Creagene (2018-2023)

Table 73. Creagene Recent Developments

Table 74. DanDrit Biotech Basic Information List

Table 75. DanDrit Biotech Description and Business Overview

Table 76. DanDrit Biotech Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 77. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of DanDrit Biotech (2018-2023)

Table 78. DanDrit Biotech Recent Developments

Table 79. DCPrime Basic Information List

Table 80. DCPrime Description and Business Overview

Table 81. DCPrime Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 82. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of DCPrime (2018-2023)

Table 83. DCPrime Recent Developments

Table 84. Sanpower Corporation Basic Information List

Table 85. Sanpower Corporation Description and Business Overview

Table 86. Sanpower Corporation Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 87. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Sanpower Corporation (2018-2023)

Table 88. Sanpower Corporation Recent Developments

Table 89. Elios Therapeutics Basic Information List

Table 90. Elios Therapeutics Description and Business Overview

Table 91. Elios Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 92. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Elios Therapeutics (2018-2023)

Table 93. Elios Therapeutics Recent Developments

Table 94. ImmunoCellular Therapeutics Basic Information List

Table 95. ImmunoCellular Therapeutics Description and Business Overview

Table 96. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 97. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of ImmunoCellular Therapeutics (2018-2023)

Table 98. ImmunoCellular Therapeutics Recent Developments

Table 99. Immunicum Basic Information List

Table 100. Immunicum Description and Business Overview

Table 101. Immunicum Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 102. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Immunicum (2018-2023)

Table 103. Immunicum Recent Developments

Table 104. Kiromic Basic Information List

Table 105. Kiromic Description and Business Overview

Table 106. Kiromic Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 107. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Kiromic (2018-2023)

Table 108. Kiromic Recent Developments

Table 109. Medigene Basic Information List

Table 110. Medigene Description and Business Overview

Table 111. Medigene Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 112. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Medigene (2018-2023)

Table 113. Medigene Recent Developments

Table 114. Merck Basic Information List

Table 115. Merck Description and Business Overview

Table 116. Merck Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 117. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Merck (2018-2023)

Table 118. Merck Recent Developments

Table 119. Northwest Biotherapeutics Basic Information List

Table 120. Northwest Biotherapeutics Description and Business Overview

Table 121. Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 122. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Northwest Biotherapeutics (2018-2023)

Table 123. Northwest Biotherapeutics Recent Developments

Table 124. Glaxo Smith Kline Basic Information List

Table 125. Glaxo Smith Kline Description and Business Overview

Table 126. Glaxo Smith Kline Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 127. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Glaxo Smith Kline (2018-2023)

Table 128. Glaxo Smith Kline Recent Developments

Table 129. Tellaorporation Basic Information List

Table 130. Tellaorporation Description and Business Overview

Table 131. Tellaorporation Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 132. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Tellaorporation (2018-2023)

Table 133. Tellaorporation Recent Developments

Table 134. Vaxil BioTherapeutics Basic Information List

Table 135. Vaxil BioTherapeutics Description and Business Overview

Table 136. Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions

Table 137. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Vaxil BioTherapeutics (2018-2023)

Table 138. Vaxil BioTherapeutics Recent Developments

Table 139. North America Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023) & (US$ Million)

Table 140. North America Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029) & (US$ Million)

Table 141. Europe Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023) & (US$ Million)

Table 142. Europe Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029) & (US$ Million)

Table 143. Asia-Pacific Dendritic Cell Cancer Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 144. Asia-Pacific Dendritic Cell Cancer Vaccines Market Size by Region (2018-2023) & (US$ Million)

Table 145. Asia-Pacific Dendritic Cell Cancer Vaccines Market Size by Region (2024-2029) & (US$ Million)

Table 146. Asia-Pacific Dendritic Cell Cancer Vaccines Market Share by Region (2018-2023)

Table 147. Asia-Pacific Dendritic Cell Cancer Vaccines Market Share by Region (2024-2029)

Table 148. Latin America Dendritic Cell Cancer Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 149. Latin America Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023) & (US$ Million)

Table 150. Latin America Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029) & (US$ Million)

Table 151. Middle East & Africa Dendritic Cell Cancer Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 152. Middle East & Africa Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023) & (US$ Million)

Table 153. Middle East & Africa Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029) & (US$ Million)

Table 154. Dendritic Cell Cancer Vaccines Market Trends

Table 155. Dendritic Cell Cancer Vaccines Market Drivers

Table 156. Dendritic Cell Cancer Vaccines Market Challenges

Table 157. Dendritic Cell Cancer Vaccines Market Restraints

Table 158. Research Programs/Design for This Report

Table 159. Key Data Information from Secondary Sources

Table 160. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Dendritic Cell Cancer Vaccines Market Size Year-over-Year 2018-2029 & (US$ Million)

Figure 2. Global Dendritic Cell Cancer Vaccines Market Size (US$ Million), 2018 VS 2022 VS 2029

Figure 3. Global Dendritic Cell Cancer Vaccines Market Share by Regions: 2022 VS 2029

Figure 4. Global Dendritic Cell Cancer Vaccines Forecasted Market Size Share by Region (2024-2029)

Figure 5. North America Dendritic Cell Cancer Vaccines Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 6. Europe Dendritic Cell Cancer Vaccines Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 7. Asia-Pacific Dendritic Cell Cancer Vaccines Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 8. Latin America Dendritic Cell Cancer Vaccines Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 9. Middle East & Africa Dendritic Cell Cancer Vaccines Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 10. Product Picture of CreaVax

Figure 11. Global CreaVax Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 12. Product Picture of Sipuleucel-T (Provenge)

Figure 13. Global Sipuleucel-T (Provenge) Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 14. Product Picture of Others

Figure 15. Global Others Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 16. Global Dendritic Cell Cancer Vaccines Market Size Share by Type: 2022 & 2029

Figure 17. North America Dendritic Cell Cancer Vaccines Revenue Market Share by Type (2018-2029)

Figure 18. Europe Dendritic Cell Cancer Vaccines Revenue Market Share by Type (2018-2029)

Figure 19. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue Market Share by Type (2018-2029)

Figure 20. Latin America Dendritic Cell Cancer Vaccines Revenue Market Share by Type (2018-2029)

Figure 21. Middle East and Africa Dendritic Cell Cancer Vaccines Revenue Market Share by Type (2018-2029)

Figure 22. Pediatrics Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 23. Adults Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 24. Global Dendritic Cell Cancer Vaccines Market Size Share by Application: 2022 & 2029

Figure 25. North America Dendritic Cell Cancer Vaccines Revenue Market Share by Application (2018-2029)

Figure 26. Europe Dendritic Cell Cancer Vaccines Revenue Market Share by Application (2018-2029)

Figure 27. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue Market Share by Application (2018-2029)

Figure 28. Latin America Dendritic Cell Cancer Vaccines Revenue Market Share by Application (2018-2029)

Figure 29. Middle East and Africa Dendritic Cell Cancer Vaccines Revenue Market Share by Application (2018-2029)

Figure 30. Dendritic Cell Cancer Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

Figure 31. Global Top 5 and Top 10 Players Dendritic Cell Cancer Vaccines Market Share in 2022

Figure 32. North America Dendritic Cell Cancer Vaccines Market Share by Country (2018-2029)

Figure 33. U.S. Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 34. Canada Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 35. Germany Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 36. France Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 37. U.K. Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 38. Italy Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 39. Russia Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 40. Nordic Countries Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 41. Asia-Pacific Dendritic Cell Cancer Vaccines Market Share by Region (2018-2029)

Figure 42. China Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 43. Japan Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 44. South Korea Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 45. Southeast Asia Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 46. India Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 47. Australia Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 48. Latin America Dendritic Cell Cancer Vaccines Market Share by Country (2018-2029)

Figure 49. Mexico Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 50. Brazil Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 51. Middle East & Africa Dendritic Cell Cancer Vaccines Market Share by Country (2018-2029)

Figure 52. Turkey Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 53. Saudi Arabia Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 54. UAE Dendritic Cell Cancer Vaccines Market Size (2018-2029) & (US$ Million)

Figure 55. Bottom-up and Top-down Approaches for This Report

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3350

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5025

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$6700

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions